Skip to main navigation Skip to search Skip to main content

Invariant natural killer t cell-activating vaccine against bacterial infections

Research output: Patent

34 Downloads (Orbit)

Abstract

Provided are vaccine compositions comprising a liposome, a bacterial polysaccharide antigen, and an invariant natural killer T (iNKT) cell agonist, methods of treating or preventing a bacterial infection using the compositions, and nasal spray devices comprising them.

Original languageEnglish
IPCA61P 31/ 04 A I
Patent numberWO2025093613
Filing date30/10/2024
Country/TerritoryInternational Bureau of the World Intellectual Property Organization (WIPO)
Priority date30/10/2023
Priority numberEP20230206743
Publication statusPublished - 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Invariant natural killer t cell-activating vaccine against bacterial infections'. Together they form a unique fingerprint.

Cite this